Source: Powered by Nasdaq Short Interest Report available via Nasdaq Data Link; Subscribe to access consolidated market short interest positions in all Nasdaq-listed securities today.

Cassava Sciences’ SAVA stock shed more than 80% of market value on Monday after the company reported that its lead pipeline drug, simufilam, failed to meet the primary endpoints in a late study ...

This is a source of deep frustration to the committee ... report by Wang's attorney or Dr. Wang so far. I am satisfied with SAVA's PR following the news. As SAVA highlights, and as acknowledged ...

On June 28, CUNY School of Medicine Professor Hoau-Yan Wang was indicted by a grand jury for allegedly falsifying data related to Cassava’s (NASDAQ:SAVA) only major drug candidate, simufilam.